BCL2 and cancer: Thus, the use of Bcl-2 protein-targeting drugs as single agents or in combination with current standard-of-care therapies could represent a concrete opportunity to overcome therapy-resistant/recurrent solid tumors and to increase the disease-free survival of cancer patients.